estrogen venous thromboembolism trial evtet randomized controlled trial rct menopausal hormone therapy postmenopausal women previous history venous thromboembolism doubleblind rct estrogen oral estradiol mgday plus progestogen norethisterone acetate neta mgday brand name kliogest versus placebo results trial published incidence vte women hormone therapy group woman placebo group events occurring within days study difference reach statistical significance sequential analysis statistically significant sequential design ignored p markers coagulation likewise increased hormone result high incidence vte treatment group trial terminated researchers concluded basis findings menopausal hormone therapy used women previous history although findings evtet studies warrant caution respect use oral estrogens women past vte research found transdermal estradiol contrast oral estradiol oral estrogens minimally influences systematic reviews metaanalyses observational studies associated increased risk vte doses similarly small study found transdermal estradiol influence coagulation women prior observational menopause estrogen venous events meve study found transdermal estradiol associated increased risk vte postmenopausal women past vte hrtooltip hazard ratio citooltip confidence interval transdermal estradiol vs hr ci oral accordingly menopausal hormone therapy guidelines state transdermal estradiol likely less risk vte recommend use transdermal estradiol women past vte high risk however rcts still needed confirm httpsenwikipediaorgwikiestrogeninvenousthromboembolismtrial